Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 71Carcinoma, Neuroendocrine 26Pheochromocytoma 23Thyroid Cancer, Papillary 21Pituitary Neoplasms 21Thyroid Neoplasms 20Adrenocortical Carcinoma 18Paraganglioma 16Multiple Endocrine Neoplasia Type 1 13Sarcoma 11Neuroblastoma 11Small Cell Lung Carcinoma 10Neoplasms 10Melanoma 9Lung Neoplasms 9Gastro-enteropancreatic neuroendocrine tumor 9Carcinoid Tumor 9Adrenal Gland Neoplasms 9Adenoma, Islet Cell 9Pancreatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Medullary 8Adenocarcinoma, Follicular 8Thyroid Carcinoma, Anaplastic 7Ovarian Neoplasms 7Neoplasm Metastasis 7Cushing Syndrome 7Cholangiocarcinoma 7Central Nervous System Neoplasms 7Carcinoma, Hepatocellular 7

Interventions

Random Allocation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoid Tumors, Intestinal × Endocrine × 90 days × Clear all
NCT07087054 2026-04-30

CAREFNDR

Crinetics Pharmaceuticals Inc.

Phase 3 Recruiting
141 enrolled
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡